OncologyEducation presents MedOncNow
In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.
21 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der OncologyEducation presents MedOncNow-Community!